A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Public ClinicalTrials.gov record NCT06685835. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
Study identification
- NCT ID
- NCT06685835
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 214 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2024
- Primary completion
- Feb 11, 2026
- Completion
- Jun 7, 2026
- Last update posted
- Jun 28, 2026
2024 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USA001 | Phoenix | Arizona | 85054-4502 | — |
| USA007 | Sacramento | California | 95815 | — |
| USA026 | Coral Gables | Florida | 33134 | — |
| USA027 | Hollywood | Florida | 33024 | — |
| USA021 | Margate | Florida | 33063 | — |
| USA018 | Miami | Florida | 33125 | — |
| USA025 | Ocala | Florida | 34470 | — |
| USA004 | Tampa | Florida | 33613 | — |
| USA010 | Weston | Florida | 33331 | — |
| USA028 | Atlanta | Georgia | 30329 | — |
| USA011 | Sandy Springs | Georgia | 30328 | — |
| USA003 | Plainfield | Indiana | 46168 | — |
| USA002 | Baton Rouge | Louisiana | 70809-2725 | — |
| USA017 | Boston | Massachusetts | 02115 | — |
| USA012 | Detroit | Michigan | 48201 | — |
| USA024 | Fort Gratiot | Michigan | 48059 | — |
| USA020 | Minneapolis | Minnesota | 55455 | — |
| USA015 | St Louis | Missouri | 63104 | — |
| USA013 | Lebanon | New Hampshire | 03766 | — |
| USA009 | Cleveland | Ohio | 44106-1716 | — |
| USA016 | Springfield | Ohio | 45505 | — |
| USA019 | Hershey | Pennsylvania | 17033-2360 | — |
| USA022 | Philadelphia | Pennsylvania | 19104-5127 | — |
| USA005 | Dallas | Texas | 75230 | — |
| USA023 | Dallas | Texas | 75231-6077 | — |
| USA008 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06685835, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 28, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06685835 live on ClinicalTrials.gov.